HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tylenol Relieves Pain For J&J Consumer As Baby Care Relaunch Loses Steam

Executive Summary

Tylenol brand boosts J&J US OTC sales 8.4% to $477m, helping balance a 24.1% decline in baby care sales due to restocking reformulated Johnson’s Baby line in 2018, mostly in the US. Firm reports consumer health sales in the US were up 1.7% to $1.39bn.

You may also be interested in...



J&J International Baby, Beauty Lines Could Lead Trimming 10% Of Consumer Portfolio

J&J plans to cut 10% of its consumer health portfolio, with most divestitures in the baby and beauty care segments outside the US. It plans to focus on growing “stronghold” categories of skin health and self care, including Aveeno and Tylenol.

J&J Starts First Baby Powder Recall Linked To Asbestos Finding

Recall announcement doesn't mention litigation J&JU faces in multiple states alleging use of Johnson's Baby Powder causes cancer due from talc in formulation. But firm's sensitivity to consumer complaints or adverse event reports linked to brand is clear with talc-related litigation as backdrop.

J&J’s Aveeno Hair-Care Relaunch Per Vogue Model Helps Drive Consumer Q2 Improvements

Company leadership has said that Vogue International – the maker of OGX and Maui Moisture hair care that J&J acquired in 2016 – would serve as a model for innovations across other brands. Strategy appears to be paying off, contributing to gains in J&J's Consumer division, which also benefited in the second quarter from Zyrtec allergy treatment and children’s Tylenol and Motrin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel